Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey

摘要: This study was conducted to analyze clinical characteristics, laboratory data, disease activity, and outcome of juvenile systemic lupus erythematosus (jSLE) patients from southern Turkey. Fifty-three with jSLE diagnosed according the revised American College Rheumatology 1997 criteria between January 2005 June 2018 were included in present study. The median age at diagnosis 12.8 (range, 5.1–17.7) years. female male ratio 9.6:1. most prevalent features mucocutaneous involvement (96.2%) constitutional manifestations (94.3%). Renal manifestations, hematological neuropsychiatric detected 40 (75%), 38 (71.7%), 13 (24.5%) patients, respectively. biopsy performed 49 (92.5%). Class IV nephritis (LN) (34%) class II LN (20.4%) common findings. Mycophenolate mofetil, cyclophosphamide corticosteroid main treatment options. Eighteen received rituximab one tocilizumab. mean SLE Disease Activity Index (SLEDAI) score time 22.47 ± 8.8 (range = 3–49), 1.34 ± 1.85 (range = 0–7) last visit. Twenty-one (39.6%) had damage agreement Systemic Lupus International Collaborating Clinics/American Damage (PedSDI; mean = 0.60 ± 0.94; range = 0–5) criteria. Growth failure cause (n = 13, 26%). One patient deceased due severe pulmonary hemorrhage multiple cerebral thromboses. this cohort have view higher frequency renal neurologic involvement. Nevertheless, multicenter studies are needed make a conclusion for all Turkish children jSLE.